Future roles of lapatinib in ErbB2-positive breast cancer: Adjuvant and neoadjuvant trials

Breast Care

Volumn 5, Issue SUPPL. 1, 2010, Pages 22-24

  Costa, Serban Dan ^a   Jackisch, Christian ^b   Thomssen, Christoph ^c  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Klinikum Offenbach   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Adjuvant; ALTTO study; ErbB2 positive breast cancer; Lapatinib; Neoadjuvant; TEACH study

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 77952798443     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000285778     Document Type: Short Survey

References (8)

1. Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23: 646-653.
2. Burstein H, Storniolo AM, Franco S, et al.: A phase II, open-label, multi-center study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol 2004;15(suppl 3):iii27.
3. Blackwell, KL, Kaplan EH, Franco SX, et al.: A phase II, open-label, multi-center study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004;22:3006.
4. Lin NU, Dieras V, Paul D, et al.: A phase II study of lapatinib for brain metastases in subjects with ErbB2-positive breast cancer following trastuzumab- based systemic therapy and cranial radiotherapy. Proc Am Soc Clin Oncol 2007;27(suppl):abstr 1012.
5. Lemieux J, Clemons M, Provencher L, et al.: The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers. Curr Oncol 2009;16:48-57.
6. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
7. Coudert BP, Arnould L, Moreau L, et al.: Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006;17:409-414.
8. Van Pelt AE, Mohsin S, Elledge RM, et al.: Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003; 4:348-353.